The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.
 
Kiyohiko Hatake
Honoraria - Kyowa Hakko Kirin; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Meiji Seika Kaisha
Research Funding - Takeda (Inst)
 
Tomohiro Kinoshita
Research Funding - Ono Pharmaceutical (Inst)
 
Noriko Fukuhara
Speakers' Bureau - Takeda
 
Ilseung Choi
No Relationships to Disclose
 
Masafumi Taniwaki
No Relationships to Disclose
 
Kiyoshi Ando
Research Funding - Kyowa Hakko Kirin (Inst)
 
Dai Maruyama
Honoraria - Celgene; Chugai Pharma; Eisai; Fujifilm; Janssen; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Mundipharma; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Takeda
 
Yasuhito Terui
No Relationships to Disclose
 
Yusuke Higuchi
No Relationships to Disclose
 
Yasushi Onishi
Speakers' Bureau - Bristol-Myers Squibb; Novartis
 
Yasunobu Abe
No Relationships to Disclose
 
Tsutomu Kobayashi
No Relationships to Disclose
 
Yukari Shirasugi
No Relationships to Disclose
 
Kensei Tobinai
Honoraria - Eisai; Mundipharma; Spectrum Pharmaceuticals; Takeda; Zenyaku Kogyo
Research Funding - Abbvie (Inst); Celgene (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Mundipharma (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Takeda (Inst)